Pierre Lafontaine - Hear Atlast MD GM
| HRAL Stock | USD 0.0004 0.0001 20.00% |
Insider
Pierre Lafontaine is MD GM of Hear Atlast Holdings
| Phone | 800-548-0783 |
| Web | https://www.hearatlastholdings.com |
Hear Atlast Management Efficiency
The company has return on total asset (ROA) of 0.27 % which means that it generated a profit of $0.27 on every $100 spent on assets. This is way below average. Hear Atlast's management efficiency ratios could be used to measure how well Hear Atlast manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Theresa Ferguson | Predictive Oncology | N/A | |
| Robert MBA | Bionano Genomics | 56 | |
| Raymond Vennare | Predictive Oncology | 71 | |
| Steven MD | Sharps Technology | 62 | |
| Jonathan Dixon | Bionano Genomics | N/A | |
| Donna Polizio | Bionano Genomics | N/A | |
| David BA | GlucoTrack | 59 | |
| Robert Myers | Predictive Oncology | 67 | |
| Andrew CPA | Sharps Technology | 68 | |
| Garry Nolan | Akoya Biosciences | 62 | |
| Marilee MBA | Akoya Biosciences | 65 | |
| Mark CPA | Bionano Genomics | N/A | |
| Erez BenZvi | GlucoTrack | 46 | |
| Robert MBA | Predictive Oncology | 69 | |
| Julia Kirshner | Predictive Oncology | N/A | |
| Frederic Pla | Akoya Biosciences | 65 | |
| Dov Elefant | Femasys | 57 | |
| MS MD | Femasys | N/A | |
| Yury Goltsev | Akoya Biosciences | N/A | |
| Mark Oldakowski | Bionano Genomics | 50 | |
| Robert Hayes | Sharps Technology | 57 | |
Management Performance
| Return On Asset | 0.27 |
Hear Atlast Holdings Leadership Team
Elected by the shareholders, the Hear Atlast's board of directors comprises two types of representatives: Hear Atlast inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hear. The board's role is to monitor Hear Atlast's management team and ensure that shareholders' interests are well served. Hear Atlast's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hear Atlast's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter CGA, Principal Officer | ||
| Pierre Lafontaine, MD GM |
Hear Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hear Atlast a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.27 | |||
| Profit Margin | 0.76 % | |||
| Operating Margin | 2.49 % | |||
| Current Valuation | 1.64 M | |||
| Shares Outstanding | 990 K | |||
| Price To Earning | 0.01 X | |||
| Price To Sales | 0.02 X | |||
| Gross Profit | 255.52 K | |||
| EBITDA | 424.01 K | |||
| Net Income | (100 K) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Hear Pink Sheet
Hear Atlast financial ratios help investors to determine whether Hear Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hear with respect to the benefits of owning Hear Atlast security.